Doctor's Notes

Adhesive-Tape Allergy in 14 Norwegian Military Personnel

Dr. Arsy #003 Life in Motion editorial illustration: Military adhesive-tape allergy evidence

Doctor’s Notes · Life in Motion · Evidence Review

Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, activity or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.

The question behind this paper

This review looks at friction-blister prevention during marches and field work. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.

Study snapshot

Study element Reported detail
Population 14 Norwegian conscripts and military personnel referred with suspected tape-related allergic contact dermatitis
Design Clinical case series with aimed patch testing and chemical analysis of medical adhesive tapes
Timepoint Evaluation after tape exposure during military service
Key result Thirteen of 14 were diagnosed with allergic contact dermatitis and reacted to colophony or modified colophony and the tape used during service; many reacted at very low test concentrations.

How to interpret the result

The investigation links a specific cluster to colophony-containing tape through clinical testing and chemical analysis. It does not support avoiding all medical tapes or self-testing adhesives.

Important limitation: This is a highly selected case series with no unexposed comparison group, so 13 of 14 is not a prevalence estimate for military personnel or tape users.

Questionnaires, examinations, patch tests, chemical analyses and trial models answer different questions. A positive screening result, symptom report or association can guide a next step, but it does not diagnose the cause of one person’s rash. Clinician-directed testing is interpreted alongside timing, distribution and verified exposures.

Questions to ask next

  • What exactly was measured: reported symptoms, visible signs, allergy, work loss, performance or quality of life?
  • Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
  • Did the design compare groups or follow change over time, and what factors could still explain the difference?
  • Would occupational-health review, clinician examination or clinician-directed testing change the practical plan?
  • What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?

Primary and authoritative sources

PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.

Where a cosmetic moisturizer fits

Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.

Bottom line

The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.

← Back to Doctor's Notes